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Backround
CAP (CEVEC’s Amniocyte Production) cells are an
immortalized cell line based on primary human amnio-
cytes. They were generated by transfection of these pri-
mary cells with a vector containing the functions E1 and
pIX of adenovirus 5. CAP cells allow for competitive
stable production of recombinant proteins with excellent
biologic activity and therapeutic efficacy as a result of
authentic human posttranslational modification. In
order to gain access to the benefits of the CAP technol-
ogy also for early research, target evaluation or assay
development, the transient expression system CAP-T
was developed. CAP-T cells are based on the original
CAP cells and additionally express the large T antigen
of simian virus 40 (SV40).
Results
To characterize the CAP-T expression system, they were
transiently transfected with an expression plasmid for
the highly complex and glycosylated human a1-Anti-
trypsin (hAAT). This resulted in remarkably high
expression levels of up to 60 mg/L. These levels could
be even increased 2.5 fold by adding an SV40 origin of
replication (SV40ori) to the expression vector (Figure 1).
When compared to HEK293T cells, CAP cells showed a
significantly higher expression titer than HEK293T cells
(data not shown). In order to understand these phenom-
ena, the copy number of the expression plasmid, upon
transfection, was determined. CAP-T efficiently repli-
cated the expression plasmid containing the SV40ori,
resulting in increasing copy numbers per cell over time
yielding in about 4 times higher copy numbers than in
HEK293T cells transfected with the same plasmid and
in CAP-T cells transfected with the plasmid lacking the
SV40ori (data not shown) and consequently in higher
expression levels. In order to establish a more scalable
transfection method than nucleofection, the suitability
of different transfection reagents for the transfection of
CAP-T cells was determined. In these experiments
beside nucleofection, 293fectin and polyethylenimin
(PEI) based transfection methods showed best results in
small scale transfections, enabling the scalability of the
transient transfection in CAP-T cells (data not shown).
With the PEI based transfection method hAAT could be
produced also in 300 mL shaking culture and 1L bior-
eactor with product titers of up to 180 mg/L in simple
batch processes of up to 10 days (data not shown). Sev-
eral other glycosylated proteins have been tested in tran-
sient transfections of CAP-T cells yielding comparable
product titers (Table 1).
Summary
In summary, CAP-T cells present a highly efficient tran-
sient expression system enabling the generation of mg
amounts of the protein of interest for early research and
development within only two weeks from gene to pro-
duct. Furthermore, CAP-T cell produced proteins
showed fully human posttranslational modification pat-
tern, which was also observed for the original human
CAP cells, the CAP-T cells were derived from. The CAP
technology based on CAP-T cells for transient transfec-
tion and CAP cells for stable protein production [1]
therefore provides a unique system in which the whole
process from early research to production of therapeutic
proteins can be run through with the same cell type.
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Figure 1 Transient expression of hAAT in CAP-T: Two plasmids containing a hAAt expression cassette were transfected by nucleofection (1 x 107
cells). The plasmid containing a SV40ori (ori) yielded about 2.5 time higher expression levels at maximum product concentration than a plasmid
lacking this ori (w/o ori).
Table 1 Table 1 summarizes the relevant data from transient transfections of CAP-T cells in different scales with
plasmids coding for different proteins of interest (hAAT, erythropoietin (EPO), C1-Inhibitor and IgG). Cells were either
transfected by nucleofection (1 x 107 cells) or by PEI (1.7 x 109 cells).
hAAT EPO C1-Inhibitor IgG
cells transfected 1 x 107 1.7 x 109 1 x 107 1 x 107 1 x 107
culture volume [ml] 30 1000 60 30 30
culture time [days] 9 6 10 12 6
viability at harvest [%] 85 70 80 87 80
volumetric productivity [mg/L] 170 180 38 35 150
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